| Lilly to lay off 8 percent of employees in bid to cut costs | | | (Reuters) - Eli Lilly and Co said on Thursday it would lay off about 8 percent of its employees as the drugmaker, which has suffered setbacks over the past year in the development of two potential blockbuster drugs, works to cut costs. |
| |
| Bristol-Myers stops kidney cancer drug test after early success | | | (Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial well ahead of schedule, despite earlier reporting mixed results on other main goals. |
| |
| U.S. FDA warns of problems with EpiPen manufacturing plant | | | (Reuters) - A U.S. regulator this week told Pfizer Inc’s Meridian Medical Technologies division, maker of the EpiPen injector device, that serious component and product failures have been associated with patient deaths and severe illness. |
| |
| Canada's top marijuana producer to double production | | | TORONTO (Reuters) - Canada's biggest licensed producer of medical marijuana has bought land next to its greenhouse production site that will allow it to more than double the total volume of cannabis it can grow, its chief executive said on Thursday. |
| |
| New Mexico sues opioid drug manufacturers, distributors | | | (Reuters) - New Mexico on Thursday sued eight opioid manufacturers and wholesale distributors, becoming the latest state or local government to file a lawsuit seeking to hold corporations accountable for a national drug addiction epidemic. |
| |
| More evidence links exercise to lower stroke risk | | | Reuters Health) - Women who consistently get the minimum recommended amount of exercise for a healthy heart may be less likely to have a stroke than their counterparts whose exercise habits shift over time, a recent U.S. study suggests. |
| |
| Positive lung drug trial opens path to U.S. market for Circassia | | | LONDON (Reuters) - AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for likely approval in the U.S., where the commercial rights are held by Britain's Circassia. |
| |
| | |
